Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Enhanced Immunoassay Validated for NGAL

By LabMedica International staff writers
Posted on 28 Jun 2017
The ectopic expression of Neutrophil Gelatinase-Associated Lipocalin (NGAL) has been reported in patients with various malignancies such as kidney, colorectal, gastric, pancreatobiliary, hepatic, breast, gynecological and hematologic cancers.

The concentration of the biomarker NGAL increases considerably immediately after acute kidney injury (AKI). More...
The measurement of NGAL in serum or plasma is also considered to be more convenient than measurement in urine, since urine output may be considerably reduced in patients with AKI.

Scientists at the University of Verona (Italy) designed a study to validate the analytical performance of the new particle-enhanced enhanced turbidimetric immunoassay (PETIA) for measuring neutrophil gelatinase-associated lipocalin (NGAL) in serum samples. The analytical validation of the NGAL PETIA consisted of calculation of limit of blank (LOB), limit of detection (LOD) and functional sensitivity, and estimation of inter-assay and intra-assay imprecision, linearity, and correlation with another widely used NGAL PETIA.

The Gentian NGAL is a particle-enhanced turbidimetric immunoassay (PETIA), which can be applied to a vast array of automated clinical chemistry analyzers. Analytical validation of the Gentian NGAL assay was carried out on a Cobas c501. The quoted NGAL serum/plasma reference range is 13.7 ng/mL to 104.6 ng/mL, the total sample volume needed for the assay is 3 μL and test results are available in 10 minutes.

An excellent correlation was observed between values measured with Gentian NGAL and BioPorto NGAL in 74 routine serum samples. The LOB and LOD of Gentian NGAL were found to be 3.8 ng/mL and 6.3 ng/mL, respectively. An analytical coefficient of variation (CV) of 20% corresponded to a NGAL value of 10 ng/mL. The intra-assay and inter-assay imprecision (CV) was between 0.4% and 5.2% and 0.6% and 7.1% and the total imprecision (CV) was 3.7%. The linearity was optimal at NGAL concentrations between 37 and 1,420 ng/mL.

The authors concluded that the result of their analytical validation show that Gentian NGAL may be a viable option for both routine and urgent assessment of serum NGAL. Additional advantages are the very fast turnaround time as results are available in approximately 10 minutes compared to 35 minutes in another commercial assay and two hours in an enzyme-linked immunosorbent assay (ELISA). The possibility of widespread implementation of this test on a wide array of clinical chemistry platforms may also permit the concomitant measurement of NGAL and other biomarkers of renal function. The full study will be published in the August 2017 issue of the journal Practical Laboratory Medicine.

Related Links:
University of Verona


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.